RELATED STUDY
Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn's disease, a randomized controlled trial
Key Findings: Resulting data revealed that the CBD abundant treatment (utilizing a cannabis chemotype II) induced significant clinical and quality of life improvement while no significant changes in inflammatory parameters or endoscopic scores were noted.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 56
Study Result: Positive
Study Location(s): Israel
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype II
Sub-Ratio: 1:4 (THC:CBD)
Dosage: Patients received either cannabis oil containing 160/40mg/ml CBD/THC or placebo for eight weeks.
Route of Administration: Oral (Ingestion)
Link to study
